FDA Peptide Reclassification 2026: What It Means for Providers Peptides in 2026, What the FDA Review Means Olympia Pharmaceuticals Orthopedic Use of BPC 157 Sports Med Review This is one of the biggest peptide regulatory updates in years, and it's just the beginning. The FDA has officially initiated the first step to reverse its 2023 stance, removing 12 peptides After being placed into FDA Category 2 in 2023, several widely discussed peptides faced restricted pathways for regulated compounding. This shift pushed demand toward unregulated markets and created significant uncertainty across the FDA considers adding a dozen peptides to its bulk drug compounding list RAPS